ArticleIrish journal of medical science2022
The effect of diabetes mellitus on disease prognosis in COVID-19 patients.
Article in Irish journal of medical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Type 2 diabetes mellitus as a predictor of severe outcomes in COVID-19 - a systematic review and meta-analyses.BMC infectious diseases · 2025Pooled it
- Association of serum amyloid A and prognosis in people with diabetes and COVID-19: A retrospective cohort study.Journal of diabetes investigation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this study, we aimed to evaluate and compare the clinical characteristics, laboratory findings, and outcomes of hospitalized patients with and without diabetes along with poorly vs. well-controlled diabetes.
methodsA total of 341 hospitalized patients with COVID-19 confirmed by RT-PCR and/or chest imaging suggestive of COVID-19 infection were retrospectively included in this study. The patients were divided into 2 groups as diabetic (n = 120) and non-diabetic (n = 221). Demographic data, symptoms, comorbidities, and laboratory values were recorded. The patients were classified according to the clinical stages defined by guidance of the WHO for COVID-19. The percentage of patients with severe disease was higher in diabetic group (n = 57) 47.5% compared to non-diabetic group (n = 61) 27.8% (p = 0.001). The percentage of patients requiring oxygen therapy was significantly higher in 61 (51.2%) diabetic group than non-diabetic group 65 (29.4%) (p = 0.001). The median duration of hospitalization in the diabetic group was 8 days [IQR 6-11.5] that was significantly higher than the non-diabetic group as 7 days [IQR 5-10] (p = 0.009). The median duration of hospitalization in poorly controlled diabetic group was 9 days [IQR 6.00-16.00] that was significantly higher than well-controlled diabetic group 8 days [IQR 6.00-11.00] (p = 0.006).
resultsPatients with diabetes were more susceptible to COVID-19 infection and the infection was more severe in patients with diabetes compared to patients without diabetes. However, the mortality rate was similar between diabetic and non-diabetic group. Diabetic COVID-19 patients without other comorbidities were not prone to severe infection.
conclusionPatients with diabetes and comorbidities, apart from the glycemic control, should receive intensive monitoring and disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.